Loading
institutionsInstitution
Cancer Research UK Manchester Institute
The Cancer Research UK Manchester Institute sits beside The Christie; Caroline Dive's group pioneered small-cell lung cancer models grown from circulating tumour cells and leads the circulating tumour DNA work of TRACERx, and the institute anchors the Manchester Cancer Research Centre.
Also called: Paterson Institute for Cancer ResearchCRUK MIPaterson Building
Overview
Founded as the Paterson Laboratories of the Christie Hospital and renamed the Cancer Research UK Manchester Institute in 2013, the institute moved into the rebuilt Paterson Building in 2023 after the 2017 fire. Director Caroline Dive's group pioneered circulating tumour cell-derived explant models of small-cell lung cancer and leads the ctDNA work of TRACERx with the Crick, and the institute anchors the Manchester Cancer Research Centre partnership and the CRUK Lung Cancer Centre of Excellence with UCL. Other groups study cancer inflammation, systems oncology, skin cancer, leukaemia biology and drug discovery. Its position within The Christie's campus gives rapid translation into early-phase trials.
Location
Manchester, GB
Type
research institute · University of Manchester
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#136 · 34 points (0 Newsweek + 0 NCI + 34 from 17 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Cancer Research UK Manchester Institute, including child institutions. 80 works · 2,627 citations · 81% open access · 8% clinical trials · 5% reviews.
Oncology works per year
322022
192023
92024
72025
132026
Most works
- Caroline Dive23 works
- Adèle C. Green15 works
- Kathryn Simpson12 works
- Dominic G. Rothwell10 works
- Simon P. Pearce9 works
- Fiona Helen Blackhall9 works
- Natalie Cook8 works
- Marit Bragelien Veierød7 works
- Paul C. Lorigan7 works
- Alastair R. W. Kerr7 works
Most cited
- Liquid biopsy and CTC-derived models
- CRUK Lung Cancer Centre of Excellence
- Manchester Cancer Research Centre
- Drug discovery
Samra Turajlić
Director
Renal cell carcinomaMelanomaCancer evolution
Medical oncologist and cancer-evolution researcher who leads the TRACERx Renal study and now directs the Cancer Research UK Manchester Institute.
Tim Somervaille
Senior Group Leader
Acute myeloid leukaemiaLeukaemia biologyHaematology
Haematologist and Senior Group Leader at CRUK Manchester Institute studying the transcriptional drivers of acute myeloid leukaemia.
Caroline Dive
Director, Cancer Research UK Manchester Institute; Professor of Cancer Pharmacology
Liquid biopsyCirculating tumour cellsSmall-cell lung cancer models
Built small-cell lung cancer models from circulating tumour cells and leads the Manchester institute.
Fiona Blackhall
Professor of Thoracic Oncology, University of Manchester; Consultant, The Christie
Lung cancerSmall-cell lung cancerBiomarker-driven trials
Fiona Blackhall is a thoracic oncologist leading small-cell lung cancer trials and biomarker research at The Christie.
Similar pages
- IdeaGrow blood-borne tumour cells to test drugs on the cells that actually spread
Shares Fiona Blackhall, Caroline Dive, Patient-derived xenografts, Liquid biopsy (ctDNA).
- IdeaCirculating tumour cell clearance as the phase 2 gate for anti-metastatic drugs
Shares Caroline Dive, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- Key paperTRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse
Shares The Francis Crick Institute, Cancer Research UK, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
- IdeaBank three spatially separate tumour blocks from every resection
Shares The Francis Crick Institute, Cancer Research UK, Comprehensive genomic profiling, Non-small-cell lung cancer.
- IdeaUse a blood test at six weeks to decide whether to keep going
Shares Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Melanoma.
- PersonAsh A. Alizadeh
Shares Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
- TrialMERMAID-1
Shares Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
- IdeaA clone report from blood at every treatment cycle
Shares Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Non-small-cell lung cancer.